Dr. Gerlinde Wernig is an Assistant Professor of Pathology at Stanford University Medical Center. After receiving her residency training in internal medicine (Germany) and pathology (US) specializing in hematology/oncology and hematopathology, she sought postdoctoral training in leukemia research and joined Gary Gilliland’s lab where she was involved in the discovery of the now famous JAKV617F mutation. She also trained with Irv Weissman’s at Stanford and did her pathology residency there. Dr. Wernig’s own lab focuses on understanding the pathomechanisms of fibrosis and inflammation with the ultimate goal to help identify new immune therapy targets and develop effective antifibrotic immune therapies. Her lab recently made the discovery that blocking of inflammatory and “don’t eat me signals” can cure fibrosis in mice in a lethal model of lung fibrosis and skin fibrosis.